B2 Indicates Obstructive Disease; B1 Indicates Parenchymal Disease
In the context of bile duct tumor thrombus (BDTT) classification in hepatocellular carcinoma, B1 represents tumor thrombus in second-order bile ducts (reflecting more localized parenchymal involvement), while B2 represents tumor thrombus in first-order bile ducts (reflecting obstructive disease with more extensive biliary involvement). 1
Understanding the B Classification System
The B1-B3 classification system specifically refers to bile duct tumor thrombus extent in hepatocellular carcinoma:
- B1: Tumor thrombus in second-order bile ducts (segmental branches)
- B2: Tumor thrombus in first-order bile ducts (sectoral branches)
- B3: Tumor thrombus in main bile ducts (left/right hepatic ducts or common hepatic duct)
Clinical Implications
B2 and B3 lesions cause obstructive biliary disease with the following features 1:
- Intrahepatic bile duct dilation (93.3% of B1-B3 cases)
- Progressive jaundice from mechanical obstruction
- The dilated ducts show no enhancement at hepatic arterial phase
- More obvious visualization at portal venous phase on CT
B1 lesions reflect parenchymal disease because:
- Tumor thrombus remains in peripheral segmental ducts
- Less likely to cause clinically significant biliary obstruction
- Often missed on preoperative imaging (none of 5 B1 patients had BDTT detected preoperatively in the study) 1
Diagnostic Approach
When evaluating conjugated hyperbilirubinemia to distinguish obstructive from parenchymal disease 2, 3:
Initial imaging with ultrasound demonstrates:
- Sensitivity 65-95% for parenchymal disease (cirrhosis, hepatitis)
- Sensitivity 32-100% for biliary obstruction
- Positive predictive value 98% for liver parenchymal disease
Key imaging finding: Intrahepatic bile duct dilation in HCC patients has 93.33% sensitivity and 98.57% specificity for diagnosing BDTT 1, making it a reliable biomarker for distinguishing obstructive (B2/B3) from parenchymal (B1) involvement.
Common Pitfall
B2 BDTT is frequently misdiagnosed preoperatively—only 3 of 12 B2 patients had BDTT identified before surgery 1. Look specifically for intrahepatic bile duct dilation on CT/MRI in HCC patients, as this finding strongly suggests B2 or B3 disease requiring different surgical planning.